2sev­en­ty bio, Bris­tol My­ers stop late-stage Abec­ma study in mul­ti­ple myelo­ma due to re­cruit­ment chal­lenges

2sev­en­ty bio and its part­ner Bris­tol My­ers Squibb said Wednes­day that they are dis­con­tin­u­ing en­roll­ment in the Phase 3 Kar­M­Ma-9 study in­ves­ti­gat­ing Abec­ma in pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER